Altimmune Inc (ALT) - Net Assets
Based on the latest financial reports, Altimmune Inc (ALT) has net assets worth $224.89 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($279.93 Million) and total liabilities ($55.04 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Altimmune Inc (ALT) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $224.89 Million |
| % of Total Assets | 80.34% |
| Annual Growth Rate | 6.03% |
| 5-Year Change | 12.93% |
| 10-Year Change | 1055.72% |
| Growth Volatility | 153.37 |
Altimmune Inc - Net Assets Trend (2005–2025)
This chart illustrates how Altimmune Inc's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Altimmune Inc for the complete picture of this company's asset base.
Annual Net Assets for Altimmune Inc (2005–2025)
The table below shows the annual net assets of Altimmune Inc from 2005 to 2025. For live valuation and market cap data, see ALT company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $224.89 Million | +82.09% |
| 2024-12-31 | $123.51 Million | -36.37% |
| 2023-12-31 | $194.10 Million | +4.75% |
| 2022-12-31 | $185.29 Million | -6.95% |
| 2021-12-31 | $199.13 Million | -11.84% |
| 2020-12-31 | $225.88 Million | +396.21% |
| 2019-12-31 | $45.52 Million | -5.78% |
| 2018-12-31 | $48.31 Million | -0.75% |
| 2017-12-31 | $48.68 Million | +150.15% |
| 2016-12-31 | $19.46 Million | +16.88% |
| 2015-12-31 | $16.65 Million | -8.89% |
| 2014-12-31 | $18.27 Million | +149.11% |
| 2013-12-31 | $7.34 Million | -37.16% |
| 2012-12-31 | $11.67 Million | -26.36% |
| 2011-12-31 | $15.85 Million | +29.82% |
| 2010-12-31 | $12.21 Million | +548.00% |
| 2009-12-31 | $1.88 Million | -90.06% |
| 2008-12-31 | $18.96 Million | -53.26% |
| 2007-12-31 | $40.57 Million | -28.96% |
| 2006-12-31 | $57.11 Million | -18.03% |
| 2005-12-31 | $69.68 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Altimmune Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 234321.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $11.00K | 0.00% |
| Other Comprehensive Income | $-4.93 Million | -2.19% |
| Other Components | $879.29 Million | 390.98% |
| Total Equity | $224.89 Million | 100.00% |
Altimmune Inc Competitors by Market Cap
The table below lists competitors of Altimmune Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ferm. Casino Mun. Canne
PA:FCMC
|
$353.17 Million |
|
Aclaris Therapeutics Inc
NASDAQ:ACRS
|
$353.21 Million |
|
Alcor Micro
TWO:8054
|
$353.24 Million |
|
Beijing Hanjian Heshan Pipeline Co Ltd
SHG:603616
|
$353.31 Million |
|
NUIX Ltd
AU:NXL
|
$352.92 Million |
|
NEL ASA ADR/30 NK -20
F:D7GA
|
$352.91 Million |
|
Digi Communications NV
RO:DIGI
|
$352.91 Million |
|
J&V Energy Tech Co Ltd
TW:6869
|
$352.91 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Altimmune Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 123,508,000 to 224,892,000, a change of 101,384,000 (82.1%).
- Net loss of 88,093,000 reduced equity.
- Share repurchases of 291,000 reduced equity.
- New share issuances of 173,733,000 increased equity.
- Other comprehensive income increased equity by 45,000.
- Other factors increased equity by 15,990,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-88.09 Million | -39.17% |
| Share Repurchases | $291.00K | -0.13% |
| Share Issuances | $173.73 Million | +77.25% |
| Other Comprehensive Income | $45.00K | +0.02% |
| Other Changes | $15.99 Million | +7.11% |
| Total Change | $- | 82.09% |
Book Value vs Market Value Analysis
This analysis compares Altimmune Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.10x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.00x to 1.10x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | $2511.49 | $2.82 | x |
| 2006-12-31 | $1219.88 | $2.82 | x |
| 2007-12-31 | $1289.03 | $2.82 | x |
| 2008-12-31 | $247.96 | $2.82 | x |
| 2009-12-31 | $20.50 | $2.82 | x |
| 2010-12-31 | $113.38 | $2.82 | x |
| 2011-12-31 | $100.47 | $2.82 | x |
| 2012-12-31 | $72.47 | $2.82 | x |
| 2013-12-31 | $43.44 | $2.82 | x |
| 2014-12-31 | $95.29 | $2.82 | x |
| 2015-12-31 | $78.06 | $2.82 | x |
| 2016-12-31 | $84.46 | $2.82 | x |
| 2017-12-31 | $114.04 | $2.82 | x |
| 2018-12-31 | $17.24 | $2.82 | x |
| 2019-12-31 | $3.47 | $2.82 | x |
| 2020-12-31 | $8.81 | $2.82 | x |
| 2021-12-31 | $4.82 | $2.82 | x |
| 2022-12-31 | $3.95 | $2.82 | x |
| 2023-12-31 | $3.65 | $2.82 | x |
| 2024-12-31 | $1.74 | $2.82 | x |
| 2025-12-31 | $2.55 | $2.82 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Altimmune Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -39.17%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -214860.98%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.24x
- Recent ROE (-39.17%) is above the historical average (-96.47%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 0.40% | 47.31% | 0.01x | 1.01x | $-6.69 Million |
| 2006 | 1.78% | 55.01% | 0.03x | 1.26x | $-4.70 Million |
| 2007 | -33.49% | -92.79% | 0.22x | 1.64x | $-17.64 Million |
| 2008 | -192.03% | -110.65% | 0.58x | 2.97x | $-38.31 Million |
| 2009 | -1713.03% | -117.17% | 0.81x | 18.08x | $-32.47 Million |
| 2010 | -285.40% | -166.00% | 0.77x | 2.23x | $-36.07 Million |
| 2011 | -23.96% | -15.65% | 1.06x | 1.44x | $-5.38 Million |
| 2012 | -42.15% | -19.54% | 1.11x | 1.95x | $-6.09 Million |
| 2013 | -159.74% | -65.42% | 1.05x | 2.34x | $-12.45 Million |
| 2014 | -54.48% | -97.70% | 0.46x | 1.20x | $-11.78 Million |
| 2015 | -20.67% | -32.34% | 0.54x | 1.19x | $-5.11 Million |
| 2016 | 996.21% | 3706.44% | 0.02x | 11.55x | $191.91 Million |
| 2017 | -95.37% | -111860.32% | 0.00x | 1.29x | $-51.29 Million |
| 2018 | -81.08% | -379.16% | 0.19x | 1.13x | $-44.00 Million |
| 2019 | -45.08% | -353.71% | 0.11x | 1.19x | $-25.07 Million |
| 2020 | -21.71% | -599.20% | 0.03x | 1.09x | $-71.63 Million |
| 2021 | -48.76% | -2201.59% | 0.02x | 1.10x | $-117.00 Million |
| 2022 | -45.72% | 0.00% | 0.00x | 1.12x | $-103.24 Million |
| 2023 | -45.57% | -20762.21% | 0.00x | 1.09x | $-107.86 Million |
| 2024 | -76.97% | -475295.00% | 0.00x | 1.13x | $-107.41 Million |
| 2025 | -39.17% | -214860.98% | 0.00x | 1.24x | $-110.58 Million |
Industry Comparison
This section compares Altimmune Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $248,191,134
- Average return on equity (ROE) among peers: -119.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Altimmune Inc (ALT) | $224.89 Million | 0.40% | 0.24x | $353.15 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $448.19K |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $169.44 Million | -45.00% | 0.21x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $518.41 Million | -52.35% | 0.08x | $3.74 Billion |
About Altimmune Inc
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.